Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791028 | 0.86 | NR1H2 (0.51) | NR1H2NR1H3HTR2B | |
| SCHEMBL6003983 | 0.78 | NR1H2 (0.39) | NR1H2NR1H3 | |
| SCHEMBL6004468 | 0.73 | ACKR3 (0.35) | ACKR3 | |
| SCHEMBL6004463 | 0.72 | ACKR3 (0.36) | NAMPTACKR3 | |
| SCHEMBL6004214 | 0.69 | TACR1 (0.33) | NR1H2NR1H3ACKR3 | |
| SCHEMBL6004209 | 0.64 | ACKR3 (0.40) | ACKR3 | |
| SCHEMBL6004212 | 0.63 | ACKR3 (0.38) | ACKR3 | |
| SCHEMBL6004473 | 0.63 | NR1H2 (0.36) | NR1H2NR1H3ACKR3 | |
| SCHEMBL10077136 | 0.62 | NAA50 (0.41) | NR1H2NR1H3 | |
| SCHEMBL4828575 | 0.62 | MAPK14 (0.48) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | NR1H2 744/4885NR1H3 723/4885SLC40A1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.